Table 1.
Baseline demographics and clinical characteristics.
| Variables (%) | All Patients (N=34) | Pembrolizumab (N=20) | Camrelizumab (N=14) |
|---|---|---|---|
| Sex | |||
| Female | 3 (8.8%) | 0 | 3 (21.4%) |
| Male | 31 (91.2%) | 20 (100%) | 11 (78.6%) |
| Age | |||
| Median (range) | 61 (47-74) | 60.5 (47-74) | 63 (55-68) |
| ECOG | |||
| 0 | 25 (73.5%) | 15 (75%) | 10 (71.4%) |
| 1 | 9 (26.5%) | 5 (25%) | 4 (28.6%) |
| BMI, kg/m2 | |||
| Median (range) | 22.2 (14.7-29.8) | 21.6 (14.7-26.0) | 22.4 (17.5-29.8) |
| Smoking | 20 (59%) | 14 (70%) | 6 (43%) |
| Alcohol addiction | 16 (47.1) | 12 (60%) | 4 (28.5%) |
| Tumor location | |||
| Middle | 25 (73.5%) | 13 (65%) | 12 (85.7%) |
| Lower | 9 (26.5%) | 7 (35%) | 2 (14.3%) |
| Clinical T stage | |||
| cT3 | 26 (76.5%) | 15 (75%) | 11 (78.6%) |
| cT4a | 8 (23.5%) | 5 (25%) | 3 (25%) |
| Clinical N stage | |||
| cN2 | 16 (47%) | 9 (45%) | 7 (50%) |
| cN3 | 18 (53%) | 11 (55%) | 7 (50%) |
| Clinical stage | |||
| III | 14 (41.2) | 8 (40%) | 6 (43%) |
| IVA | 20 (58.8) | 12 (60%) | 8 (57%) |
| Grade | |||
| G1 | 1 (3%) | 1 (5%) | 0 |
| G2 | 13 (38.2%) | 9 (45%) | 4 (28.6%) |
| G3 | 9 (26.5%) | 4 (20%) | 5 (35.7%) |
| GX | 11 (32.3%) | 6 (30%) | 5 (35.7%) |